Mycosis fungoides
Drug research and approvals for mycosis fungoides: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 29 studies of mycosis fungoides are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, FDA has 3 approved and 5 open orphan designations naming it, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 29
- Trials authorized in Canada: 2
- FDA orphan approvals: 3
- EU medicines: 2
- A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin LymphomaNCT07192471 · Phase 1 · Kyowa Kirin, Inc. · starts Sep 2, 2026
- Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceNCT07132567 · Not reported · Kyowa Kirin Co., Ltd. · starts May 2, 2025
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)NCT07021495 · Not reported · Leiden University Medical Center · starts Jul 29, 2025
- A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or…NCT07003100 · Not reported · City of Hope Medical Center · starts Dec 6, 2024
- A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLNCT06854653 · Phase 2 · Prescient Therapeutics, Ltd. · starts Mar 28, 2025
- JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasNCT06716658 · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China · starts Dec 25, 2024
- Systemic Therapies in the Treatment of Cutaneous T-cell LymphomaNCT06588868 · Not reported · Fondazione Italiana Linfomi - ETS · starts Feb 27, 2025
- Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot TrialNCT06580002 · Phase 2 · University of California, Irvine · starts Dec 2, 2024
- Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaNCT06508463 · Phase 1 · Mayo Clinic · starts Jan 5, 2024
Approved 6
- MechlorethamineDNA inhibitor
- MogamulizumabC-C chemokine receptor type 4 cross-linking agent
- MethotrexateDihydrofolate reductase inhibitor
- PrednisoneGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
Phase 3 6
- Brentuximab vedotinTubulin inhibitor
- Hypericin
- BexaroteneRetinoid X receptor agonist
- MethoxsalenDNA inhibitor
- NaloxoneOpioid receptors; mu/kappa/delta antagonist
- ZanolimumabT-cell surface antigen CD4 other
Phase 2 12 of 17
- PembrolizumabProgrammed cell death protein 1 inhibitor
- VorinostatHistone deacetylase 1 inhibitor
- AlemtuzumabCAMPATH-1 antigen inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- ResimmuneElongation factor 2 inhibitor
- Edodekin alfa
- Resminostat
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- IsotretinoinRetinoic acid receptor agonist
- NelarabineDNA inhibitor
- RosiglitazonePeroxisome proliferator-activated receptor gamma agonist
Phase 1 or earlier 12 of 33
- RomidepsinHistone deacetylase inhibitor
- Fludarabine
- Carfilzomib26S proteasome inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- AgatolimodToll-like receptor 9 agonist
- TanespimycinHeat shock protein HSP90 inhibitor
- CyclosporineCyclophilin A modulator
- IrinotecanDNA topoisomerase I inhibitor
- TrastuzumabReceptor protein-tyrosine kinase erbB-2 inhibitor
- AldesleukinInterleukin-2 receptor agonist
- DuvelisibPI3-kinase p110-delta subunit inhibitor
- ObinutuzumabB-lymphocyte antigen CD20 binding agent
How its trials ended
231 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 82 whose ending is known, 30% met their primary endpoint, 0% missed it and 70% stopped early.
- Completed, result not reported8738%
- Ongoing5022%
- Met its primary endpoint2511%
- Stopped: other or unclear2511%
- Stopped: enrollment or feasibility177%
- Status unknown125%
- Stopped: sponsor or business decision73%
- Stopped: funding52%
- Stopped: lack of efficacy31%
| Nov 18, 2022 | An interventional, single-arm, open-label phase II study investigating the efficacy and safety of ANTI-PD1 immunotherapy for the treatment of patients with…Libtayo (cemiplimab) | Alberta Health Services, Cross Cancer Institute | Pending |
| Dec 13, 2018 | A phase 1 dose escalation trial of intratumoral injections of TTI-621 in subjects with relapsed and refractory percutaneously-accessible solid tumors and…TTI-621 (SIRPA-IGG1 fc) | Trillium Therapeutics | Pending |
| Aug 8, 2018 | PoteligeoPOTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after… | Kyowa Kirin Pharmaceutical Development Inc. | Approved |
| Nov 9, 2017 | AdcetrisTreatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy | Seagen Inc. | Approved |
| Aug 23, 2013 | ValchlorTopical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed… | Helsinn Birex Pharmaceuticals Ltd. | Approved |
| Sep 18, 2017 | PriliximabTreatment of mycosis fungoides (MF) | Onco Therapies, Inc. | Designated |
| Mar 30, 2017 | MRG-106 oligonucleotide inhibitor of microRNA miR-155-5pTreatment of mycosis fungoides | miRagen Therapeutics, Inc. | Designated |
| Nov 23, 2010 | NaloxoneTopical treatment of pruritus associated with mycosis fungoides | Elorac, Inc. | Designated |
| Aug 13, 2004 | Human anti-CD4 monoclonal antibodyTreatment of mycosis fungoides | Emergent Product Development Seattle, LLC | Designated |
| Oct 15, 1990 | Methotrexate with laurocapramTopical treatment of mycosis fungoides. | Echo Therapeutics, Ltd. | Designated |
| Nov 22, 2018 | PoteligeoMogamulizumab · orphan | Kyowa Kirin Holdings B.V. | EMA ↗ |
| Mar 3, 2017 | LedagaChlormethine · orphan | Helsinn Birex Pharmaceuticals Ltd. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA